Posted by Michael Wonder on 30 Oct 2023
bluebird bio enters into advance agreement to sell priority review voucher, if granted, for $103 million
30 October 2023 - bluebird bio today announced that it has entered into an agreement to sell a rare paediatric disease priority review voucher, if received, in connection with the potential approval of lovotibeglogene autotemcel for sickle cell disease.
Under the terms of the agreement, rights to the voucher will transfer to the buyer and the Company will receive $103 million upon closing of the sale, which is contingent upon the US FDA’s approval of the biologics license application for lovotibeglogene autotemcel and granting of the voucher.
